<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447784</url>
  </required_header>
  <id_info>
    <org_study_id>TH002</org_study_id>
    <nct_id>NCT01447784</nct_id>
  </id_info>
  <brief_title>ToleroMune House Dust Mites (HDM) Exposure Chamber Study</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and&#xD;
      fabric. Like many other allergens, exposure to HDM allergens in sensitised patients is&#xD;
      associated with poorer lung function, greater medication requirements and more asthma&#xD;
      symptoms as well as chronic rhinosinusitis symptoms. In contrast to other allergens, there is&#xD;
      evidence that HDMA leads to the development of asthma, in addition to exacerbating&#xD;
      pre-existing asthma in HDM-sensitised patients.&#xD;
&#xD;
      ToleroMune HDM is a novel, synthetic, allergen-derived peptide desensitising vaccine,&#xD;
      currently being developed for the treatment of HDM allergy&#xD;
&#xD;
      This study will look at the efficacy, safety and tolerability of three doses of ToleroMune&#xD;
      HDM in HDM allergic subjects following challenge with HDM allergen in an Environmental&#xD;
      Exposure Chamber (EEC)).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised, double-blind, placebo-controlled, parallel group&#xD;
      study to evaluate the safety and tolerability of ToleroMune HDM in HDM allergic subjects with&#xD;
      allergic rhinoconjunctivitis. The efficacy of ToleroMune Ragweed will be explored in subjects&#xD;
      using an EEC.&#xD;
&#xD;
      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a&#xD;
      maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic,&#xD;
      at the Investigator's discretion. Baseline Challenge will consist of 3 visits to the EEC.&#xD;
      Eligible subjects will complete a daily diary card at home for two weeks following the final&#xD;
      visit to the EEC.&#xD;
&#xD;
      In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be&#xD;
      randomised to one of four groups and will receive treatment over 11 visits in 3 dosing&#xD;
      periods for each subject. Within each dosing period visits will take place at intervals of 4&#xD;
      weeks (28Â±2 days). There will also be two EEC visits during the treatment period and one post&#xD;
      treatment EEC visit. Following the final visit to the EEC, subjects will complete a daily&#xD;
      diary card at home for two weeks.&#xD;
&#xD;
      In Period 3, Follow-up will be conducted 16-21 days after the final EEC visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Up to 47 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores for nasal and non-nasal symptoms</measure>
    <time_frame>Up to 47 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Up to 19 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDM specific IgA</measure>
    <time_frame>Up to 53 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDM specific IgE</measure>
    <time_frame>Up to 53 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDM specific IgG4</measure>
    <time_frame>Up to 53 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Upto 53 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune HDM Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune HDM Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune HDM Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ToleroMune HDM</intervention_name>
    <description>Intradermal injection 1 x 11 administrations 4 weeks apart</description>
    <arm_group_label>ToleroMune HDM Dose 1</arm_group_label>
    <arm_group_label>ToleroMune HDM Dose 2</arm_group_label>
    <arm_group_label>ToleroMune HDM Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection 1 x 11 administrations 4 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Male or female, aged 18-65 years.&#xD;
&#xD;
          -  Minimum 1-year documented history of rhinoconjunctivitis on exposure to HDM.&#xD;
&#xD;
          -  Positive skin prick test to Der p allergen.&#xD;
&#xD;
          -  Minimum qualifying rhinoconjunctivitis symptom scores&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  History of asthma (asthma in childhood .&#xD;
&#xD;
          -  A history of anaphylaxis to HDM allergen.&#xD;
&#xD;
          -  Subjects with an FEV1 &lt;80% of predicted.&#xD;
&#xD;
          -  Subjects who cannot tolerate baseline challenge in the EEC.&#xD;
&#xD;
          -  Subjects for whom administration of epinephrine is contra-indicated (e.g. subjects&#xD;
             with acute or chronic symptomatic coronary heart disease or severe hypertension).&#xD;
&#xD;
          -  A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.&#xD;
&#xD;
          -  A history of any significant disease or disorder (e.g. cardiovascular, pulmonary,&#xD;
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,&#xD;
             neoplastic/malignant, psychiatric, major physical impairment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen Patel, MD, CCFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HDM allergy</keyword>
  <keyword>Rhinoconunctivitis</keyword>
  <keyword>Environmental Exposure Chamber</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>ToleroMune HDM</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

